Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemic-euglycaemic clamp.

As the first demonstration of the insulin-sensitizing action of apelin in humans, alongside numerous studies in rodents, this trial confirms that the apelin/APJ pathway should be considered as a new target to design alternative therapeutic strategies to control insulin resistance in type 2 diabetic patients.